Clinical Trial

The Effect of GD-iExo-003 in Acute Ischemic Stroke

Study acronym: ExoCURE
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated December 4, 2025 (before its estimated March 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, randomized, double-blinded, placebo-controlled, dose-escalation trial. The objective of this study is evaluating safety and preliminary efficacy of intravenous exosomes derived from human induced pluripotent stem cell (GD-iExo-003) in acute ischemic stroke.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2023-11-15; most recent amendment 2025-11-26.
Status change: Not Yet Recruiting → Recruiting 2024-05-23
Trial Details
NCT Number NCT06138210
Lead Sponsor Xuanwu Hospital, Beijing
Collaborators: Guidon Pharmaceutics Ltd.
Conditions Acute Ischemic Stroke
Enrollment 29 participants
Start Date 2024-06-05
Primary Completion 2026-03-30 (estimated)
Study Completion 2026-03-30 (estimated)
Updated on ClinicalTrials.gov 2025-12-04